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 Abstract 
 Objective: To compare the effects of biliopancreatic diversion (BPD) and laparoscopic gastric 
banding (LAGB) on insulin sensitivity and secretion with the effects of laparoscopic gastric 
plication (P).  Methods: A total of 52 obese women (age 30–66 years) suffering from type 2 
diabetes mellitus (T2DM) were prospectively recruited into three study groups: 16 BPD; 16 
LAGB, and 20 P. Euglycemic clamps and mixed meal tolerance tests were performed before, 
at 1 month and at 6 months after bariatric surgery. Beta cell function derived from the meal 
test parameters was evaluated using mathematical modeling.  Results: Glucose disposal per 
kilogram of fat free mass (a marker of peripheral insulin sensitivity) increased significantly in 
all groups, especially after 1 month. Basal insulin secretion decreased significantly after all 
three types of operations, with the most marked decrease after BPD compared with P and 
 Received: April 14, 2016 
 Accepted: October 27, 2016 
 Published online: December 13, 2016 
 Prof. Dr. Martin Fried 
 OB Klinika 
 Pod Krejcárkem 975 
 130 00 Prague 3, Czech Republic 
 docfried  @  volny.cz 
www.karger.com/ofa
 DOI: 10.1159/000453000 
This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 Interna-
tional License (CC BY-NC-ND) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribu-
tion for commercial purposes as well as any distribution of modified material requires written permission.
D
ow
nl
oa
de
d 
by
: 
As
to
n 
Un
ive
rs
ity
-C
on
so
lid
at
io
n 
   
   
   
   
   
   
   
   
13
4.
15
1.
16
.1
68
 - 
12
/1
9/
20
16
 1
:2
5:
03
 P
M
411Obes Facts 2016;9:410–423
 DOI: 10.1159/000453000 
 Vrbikova et al.: Insulin Sensitivity and Secretion in Obese Type 2 Diabetic Women after 
Various Bariatric Operations 
www.karger.com/ofa
© 2016 The Author(s). Published by S. Karger GmbH, Freiburg
LAGB. Total insulin secretion decreased significantly only following the BPD. Beta cell glucose 
sensitivity did not change significantly post-surgery in any of the study groups.  Conclusion: 
We documented similar improvement in insulin sensitivity in obese T2DM women after all 
three study operations during the 6-month postoperative follow-up. Notably, only BPD led to 
decreased demand on beta cells (decreased integrated insulin secretion), but without increas-
ing the beta cell glucose sensitivity.  © 2016 The Author(s)
Published by S. Karger GmbH, Freiburg 
 Introduction 
 Bariatric surgery can lead to significant improvement of type 2 diabetes mellitus (T2DM) 
in morbidly obese patients  [1, 2] . A meta-analysis by Buchwald et al.  [3] has shown that lapa-
roscopic adjustable gastric banding (LAGB) and biliopancreatic diversion (BPD) induces 
remission of T2DM in 50% and up to 95% of bariatric T2DM patients, respectively. Weight 
loss dependent improvement in insulin sensitivity is regarded as the main mechanism for 
T2DM improvement/remission after LAGB (restrictive bariatric procedure)  [1, 2, 4] . 
However, following BPD (a predominantly malabsorptive procedure) improvement in 
insulin sensitivity has been demonstrated even within a few days after the operation and, 
thus, is not only weight loss-dependent  [1, 2, 4] . The underlying mechanisms leading to 
T2DM improvement/remission following more complex bariatric procedures such as the 
BPD are not fully clarified yet and appear to involve changes not only in insulin resistance 
but also in insulin and incretin secretion  [4, 5] . Novel bariatric procedures such as the lapa-
roscopic gastric plication (P), also referred to as laparoscopic greater curvature plication, 
total gastric vertical plication, or gastric imbrication  [5–8] , recently has broadened the 
arsenal of metabolic surgery interventions for the treatment of obese T2DM patients. This 
newer procedure eliminates the greater gastric curvature and forms a gastric tube by lapa-
roscopic plication/infolding of the greater gastric curvature through placement of one or 
two rows of non-absorbable sutures or staples, thus reducing the stomach volume and 
leading to a restrictive effect without utilizing implantable devices (e.g., gastric band), 
gastrectomy, or intestinal bypass. Previously, the greater and lesser curvature were used for 
the creation of an intraluminal fold of the stomach, however the greater curvature was found 
to be more effective  [9] . To date, there are limited data on the effects of this emerging surgical 
technique in T2DM patients compared to established bariatric procedures. In the present 
study, we therefore aimed to compare the effects of LAGB, BPD and P on insulin resistance 
and secretion in obese T2DM women. 
 Patients and Methods 
 Study Subjects 
 For the purposes of this study, we prospectively recruited 52 morbidly obese women (BMI  ≥ 35 kg/m 2 ) 
with T2DM (age 30–66 years; T2DM duration 1–14 years). Obese T2DM women eligible for bariatric surgery 
were allocated to the three different bariatric procedures of the study according to consecutive numbers, 
which were assigned at the beginning of the indication/screening process for study enrollment, providing 
that there were no contraindications for a particular operation type. In the context of this study, further 
exclusion criteria included: treatment with either glitazones or DPP-IV inhibitors or GLP1 agonists; evidence 
or history of clinically significant cardiovascular, pulmonary, endocrine (other than obesity and T2DM), 
hematological, renal, gastrointestinal, hepatic (other than NAFLD), neurologic, psychiatric, inflammatory, or 
severe allergic disease; cancer; pregnancy or breastfeeding; weight change more than a 5% of the total body 
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weight over the preceding 12 weeks, or recent changes in exercise intensity and/or frequency over the 
preceding 4 weeks before surgery. 
 In total, 16 subjects underwent BPD; 16 subjects LAGB; and 20 subjects P. For 13 patients included in 
the P study group, non-comparative, prospective, results without analyses of beta cell function data via math-
ematical modeling have been previously described by our group in the pilot paper on the effects of gastric 
plication in T2DM  [6] . 
 Age and T2DM duration did not significantly differ between the three study groups ( table 1 ). Antidia-
betic treatment was as follows: 
 – In the BPD group, 2 subjects were on diet only; 11 subjects were treated with metformin only and 3 
subjects with a metformin-sulphonylurea combination.  
 – In the LAGB group, 9 subjects were treated with metformin only, 1 subject with a metformin-
sulphonylurea combination, 3 subjects with sulphonylurea only, 1 subject with metformin and insulin, 
and 1 subject with a metformin-sulphonylurea combination and insulin. 
 – In the P group, 2 subjects were treated with diet only, 15 subjects with metformin only, 2 subjects 
with a metformin-sulphonylurea combination, and 1 subject with metformin and insulin. 
 Study Surgical Procedures 
 All three types of bariatric procedures of this study were performed laparoscopically and according to 
established techniques, with standard peri- and postoperative care, as previously described in the literature 
 [6, 7, 10] . Briefly, these three bariatric procedures were performed as follows:
 – BPD was performed according to Scopinaro’s standard procedure, but with a 90 cm common channel 
instead of the 50 cm one originally suggested by Scopinaro  [10] . Intestinal measurements were taken 
on the bowel fully stretched, at half-way from the mesenteric and the antimesenteric border. A 
Table 1.  Age, T2DM duration and key weight/anthropometric-related parameters of the obese T2DM women in the three study 
groups before the bariatric operation (Exam 1), and the effects of BPD, LAGB or P on these parameters at 1 month (Exam 2) and 
6 months (Exam 3) after the operation
Par ameter Operation Exam 1 Exam 2 Exam 3 ANOVA††
Age, years BPD (a) 50.6 (47.1; 53.7)   
LAGB (b) 54.8 (51.8; 57.5)  
P (c) 53 (50.1; 55.5)    
DM duration, years BPD (a) 3.48 (2.49; 4.78)  
LAGB (b) 3.18 (2.24; 4.43)  
P (c) 3.35 (2.48; 4.46)  
BMI, kg/m2 BPD (a) 44.9 (43.8; 45.9) 41.7 (40.8; 42.7) 37.7 (36.9; 38.5) operation***, 
exam***, subject***, 
operation × exam*
LAGB (b) 42.2 (41.4; 43.0) 40.1 (39.3; 40.8) 38.3 (37.6; 39.0)
P (c) 42.4 (41.7; 43.2) 39.5 (38.8; 40.2) 37.7 (37.2; 38.4)
a–b, a–c, b–c+ Exam 1 (a) Exam 2 (b) Exam 3 (c) a–b, a–c, b–c
FFM, kg BPD (a) 60.3 (58.7; 62.2) 55.5 (54.1; 57.0) 55.5 (54.2; 56.9) exam***, subj***
LAGB (b) 58.8 (57.5; 60.3) 56.2 (54.9; 57.6) 54.9 (53.7; 56.1)
P (c) 58.2 (56.9; 59.6) 56.5 (55.3; 57.7) 55.3 (54.2; 56.5)
a–b, a–c, b–c Exam 1 (a) Exam 2 (b) Exam 3 (c) a–b, a–c, b–c
Waist circumference, cm BPD (a) 126 (122; 130) 125 (121; 129) 111 (108; 114)  exam***, subject***, 
operation × exam**LAGB (b) 121 (118; 124) 115 (112; 117) 114 (112; 117)
P (c) 122 (119; 124) 115 (113; 118) 113 (110; 115)
a–b, a–c, b–c Exam 1 (a) Exam 2 (b) Exam 3 (c) a–b, a–c, b–c
 +Significant difference for multiple comparisons (p<0.05); significant difference for ANOVA factors and between-factor 
interaction *p<0.05, **p<0.01, ***p<0.001. 
††Adjusted for age and BMI.
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relatively larger stomach remnant (up to 400 ml) was also left, aiming to potentially decrease the risk 
of severe postoperative nutritional deficiencies.  
 – The LAGB (MiniMizer Extra adjustable gastric band, Bariatric Solutions GmbH, Stein am Rhein, 
Switzerland) was placed using the standardized pars flaccida technique  [7] . 
 – P was performed in standardized fashion, starting the dissection 3–5 cm proximally to the pylorus 
and stopping approximately 2 cm below the angle of His. Through this dissection, the greater 
curvature was fully infolded and secured. A 36 F bougie was used for calibration of the stomach tube 
during the infolding of the stomach in order to maintain a standardized stomach lumen  [6] .  
 None of the patients in this study exhibited major intraoperative and/or postoperative complications.
 Body Composition  
 Anthropometric measurements were performed in all patients at three time points (i.e., before the oper-
ation and at 1 month and 6 months after the operation), as per protocol. Body weight was measured to the 
nearest 0.5 kg and height to the nearest 1 cm. BMI was calculated as body weight in kilograms divided by the 
square of the height in meters. Waist circumference was measured in standing position, at the half of the 
distance between lower ribs and the iliac crest. Hip circumference was measured as the widest gluteal 
circumference. Fat free mass (FFM) was measured using a standardized calibrated bioimpedance instrument 
(TBF-300; Tanita ® Corp., Arlington Heights, IL, USA).
 Study Protocol Exams 
 For each study participant a mixed meal tolerance test (MMT) and an euglycemic clamp test were 
performed in 2 subsequent days before the operation (Exam 1) and at 1 month (Exam 2) and 6 months (Exam 
3) after the operation. Oral antidiabetic drugs and long-acting insulin was discontinued 3 days and 24 h 
before the scheduled study examinations, respectively. In the context of this study, T2DM improvement or 
resolution at 6 months (Exam 3) was defined according to the European guidelines on metabolic and bariatric 
surgery  [11] , although these are recommended based on the 1-year post-operative follow-up.
 MMT  
 A standardized liquid MMT (300 ml; 375 kcal; 1,581 kJ; 30% (28.2 g) protein, 25% (10.5 g) fat, 45% (42 
g) carbohydrate) was performed at each of the three study time points, namely at baseline (Exam 1), at 1 
month (Exam 2) and at 6 months (Exam 3) after the operation. All patients were tested in the morning after 
overnight fasting, and venous blood was sampled for measurements of gastric inhibitory polypeptide (GIP), 
glucagon-like peptide-1 (GLP-1), and glucagon at 0, 30, 60, 90, 120, and 180 min after the liquid meal 
ingestion. These blood samples were collected into chilled ethylene-diamine-tetraacetic acid(EDTA)-
containing tubes with aprotinin. Dipeptidyl-peptidase-4 (DPP-IV) inhibitor (Merck Millipore Corp., Billerica, 
MA, USA) was added immediately after blood sampling. Blood samples were also collected into chilled EDTA-
containing tubes without aprotinin for assessment of glucose, insulin and C-peptide levels at –15, –10, 0, 15, 
30, 45, 60, 90, 120, 150, and 180 min. All samples were immediately cooled, and plasma was prepared, 
aliquoted, and stored at –80 ° C until assayed. Plasma levels of blood glucose (photometric method with hexo-
kinase), insulin (electro-chemiluminiscence immunoassay; ECLIA), C-peptide (ECLIA), and glycated hemo-
globin (HbA1c, immunoturbidimetric method) were measured using the Cobas ® 6000 analyzer (Roche Diag-
nostics, Rotkreuz, Switzerland). Plasma concentrations of GIP, GLP-1, and glucagon were assessed using a 
multiplex assay (Bio-Plex Pro TM Human Diabetes Assay Panel, BioPlex ® 200 System; Bio-Rad Laboratories, 
Cressier, Switzerland).
 Euglycemic Clamp and Insulin Sensitivity Indices 
 On the next day following each MMT and after overnight fasting, an euglycemic hyperinsulinemic clamp 
was performed, as previously described  [12] . Briefly, after inserting a cannula in a dorsal hand vein for 
sampling of arterialized venous blood and another one into the antecubital fossa for infusions, subjects 
rested at least for 30 min in the supine position. Subsequently, the hand with the dorsal hand cannula was 
placed into a heated blanket in order to get arterialized blood for measuring blood glucose levels, which were 
maintained at 5 mmol/l via a variable 15% glucose infusion. Insulin was delivered by the primed constant 
infusion of 240 pmol/min/m 2 . Glucose disposal (Mk value), as the ‘gold standard’ for peripheral insulin sensi-
tivity measurements, was calculated during the last 30-min period of the clamp test, related to fat free mass 
(in μmol/min/kg).
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 The homeostatic model assessment (HOMA) method was also applied to assess insulin resistance 
(HOMA-IR) based on the fasting glucose and insulin levels according to the following formula: HOMA-IR = 
(fasting glucose (mmol/l) × fasting insulin (mIU/l)) / 22.5, as previously described  [13] . This index reflects 
more the hepatic insulin sensitivity rather than the whole body/peripheral one. 
 Beta Cell Function and Hepatic Insulin Extraction 
 Beta cell function was assessed by mathematical modeling, as previously described  [14] . Briefly, insulin 
secretion is described as the sum of two components, i.e., S g (t) and S d (t). The first term, Sg(t), is that origi-
nating from a dose-response function (f(G)); the dose response is modulated by a function of time (P(t)) that 
averages one during the MMT and increases with time, thus determining the late insulin secretion 
enhancement. The term P(t) modulating the dose response is denoted as the potentiation factor.
 The second term, Sd(t), describes the early response. This is proportional to the time derivative of 
glucose concentration when it is positive and is otherwise zero. Thus, this component is significant as long 
as the glucose concentration is increasing, i.e., in the early phase of the MMT. The proportionality constant of 
the early secretion component (Kd) is termed rate sensitivity. 
 As such, the primary results obtained from this modeling analysis are: the dose response (f(G)), the 
potentiation factor (P(t)), and the rate sensitivity (scalar parameter).
 Because f(G) and P(t) are functions (of glucose concentration and time, respectively), other scalar 
parameters are derived from them. Hence, two parameters characterizing the dose response are calculated: 
the slope of the dose response, denoted as glucose sensitivity, and insulin secretion at a fixed glucose level, 
which is representative of the basal glucose value (e.g., 5 mmol/l in subjects with normal glucose tolerance). 
The potentiation factor excursions are typically quantified using the ratio between the value at 2 h and the 
basal value (potentiation ratio). In addition to these parameters, the modeling analysis provides basal insulin 
secretion and total insulin secretion (the integral of insulin secretion during the whole MMT). Insulin 
secretion is calculated from C-peptide deconvolution using the method by Van Cauter et al.  [15] and is 
expressed in pmol/min/m 2 of estimated body surface area.
 Finally, hepatic insulin extraction was computed in the basal state as the molar ratio of C-peptide to 
insulin levels.
 Statistical Analysis 
 The relationships between individual metric variables and factors were evaluated by ANOVA models 
followed by least significant difference multiple comparisons. The first model, used for the evaluation of 
anthropometric, basal state and euglycemic hyperinsulinemic clamp-derived parameters, consisted of 
subject factor (separating inter-individual variability from remaining factors), between-subject factor oper-
ation, within-subject factor exam and operation × exam interaction. The second model, used for the evalu-
ation of the MMT time curves, consisted of subject factor, between-subject factor operation, within-subject 
factors exam and time, and all interactions between these factors. The original raw data were transformed 
by a power transformation to attain symmetric data distribution and constant variance. The homogeneity of 
data was checked using residual analysis, as previously reported  [16, 17] . The results are presented as mean 
(lower limit of CI; upper limit of CI) unless stated otherwise. Statistical significance was set at p < 0.05. Both 
ANOVA models were adjusted to constant initial BMI, age and initial values of the dependent variable. These 
variables were divided into two groups ( ≤ median, >median) and the corresponding dichotomous variables 
were added into the model.
 Results 
 Effects on Weight Loss-Related Parameters  
 Table 1 presents the outcomes relating to selected weight loss-related parameters in the 
three study groups. BMI was the highest in the BPD group, followed by the LAGB and the P 
group (operation: F = 6; p < 0.001). BMI decreased in a similar way in the P and LAGB groups 
and more markedly in the BPD group, both between Exam 1 and 2 and from Exam 2 to 3. 
Furthermore, waist circumference and FFM decreased in a similar way in the LAGB and P 
groups and more markedly in the BPD group ( table 1 ). 
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Table 2.  Effects of BPD, LAGB, and P on key blood glucose- and insulin-related parameters at 1 month (Exam 2) and 6 months 
(Exam 3) after the operation (Exam 1: baseline levels before the bariatric operation)
Parameter Operation Exam 1 Exam 2 Exam 3 ANOVA††
Fasting blood 
glucose, mmol/l
BPD (a) 8.07 (7.51; 8.70) 6.56 (6.17; 6.99) 6.26 (5.86; 6.69) operation*, exam***, 
subject**LAGB (b) 8.81 (8.23; 9.46) 7.06 (6.67; 7.49) 6.92 (6.55; 7.34)
P (c) 8.33 (7.83; 8.89) 7.23 (6.85; 7.66) 6.84 (6.47; 7.24)
a-b, a-c, b-c Exam 1 (a) Exam 2 (b) Exam 3 (c) a–b, a–c, b–c
Blood glucose at 
120th min, mmol/l
BPD (a) 9.63 (8.72; 10.69) 6.53 (5.99; 7.13) 7.18 (6.55; 7.91) exam***, subject**
LAGB (b) 9.74 (8.93; 10.67) 8.05 (7.43; 8.75) 7.59 (7.02; 8.23)
P (c) 9.71 (8.93; 10.59) 7.61 (7.06; 8.23) 7.79 (7.21; 8.46)
a-b, a-c Exam 1 (a) Exam 2 (b) Exam 3 (c) a–b, a–c
Glycated hemoglobin, 
mmol/mol
BPD (a) 46.9 (45.9; 48.1) 42.4 (41.7; 43.1) 42.4 (41.6; 43.2) operation***, exam***, 
subject***, operation 
× exam*
LAGB (b) 48.5 (47.5; 49.5) 45.5 (44.7; 46.4) 45.0 (44.3; 45.8)
P (c) 47.6 (46.7; 48.6) 45.6 (44.8; 46.4) 45.4 (44.6; 46.2)
a-b, a-c, b-c Exam 1 (a) Exam 2 (b) Exam 3 (c) a–b, a–c, b–c
HOMA-IR BPD (a) 9.19 (7.59; 11.23) 3.89 (3.23; 4.69) 3.56 (2.98; 4.25) exam***, subject***
LAGB (b) 9.62 (8.12; 11.47) 4.68 (4.01; 5.47) 4.66 (3.99; 5.44)
P (c) 9.07 (7.72; 10.72) 5.12 (4.37; 6.03) 4.84 (4.17; 5.63)
 Exam 1 (a) Exam 2 (b) Exam 3 (c) a–b, a–c, b–c
Mkper FFM, mmol/
min/kg
BPD (a) 15.6 (12.4; 19.1) 28.5 (24.2; 33.3) 32.6 (28.2; 37.5) exam***, subject**
LAGB (b) 17.4 (14.6; 20.4) 26.1 (22.5; 30.0) 28.5 (24.9; 32.4)
P (c) 20.2 (17.5; 23.2) 27.2 (23.9; 30.6) 29.0 (25.7; 32.6)
a-c, b-c exam 1 (a) exam 2 (b) exam 3 (c) a–b, a–c
Basal insulin 
secretion, pmol/
min/m2
BPD (a) 177.5 (162.6; 194.1) 146.7 (133.7; 161) 127.4 (116.1; 139.7)  exam***, subject***
LAGB (b) 185.4 (171.5; 200.4) 142 (131.5; 153.3) 139.6 (129.3; 150.7)
P (c) 162.5 (150.9; 175.1) 151.8 (140.6; 164) 142.9 (132.4; 154.3)
a-b, a-c, b-c Exam 1 (a) Exam 2 (b) Exam 3 (c) a–b, a–c, b–c
Total insulin 
se cretion, nmol/m2
BPD (a) 61.3 (55.9; 67.1) 35.8 (32.0; 39.9) 38.9 (34.8; 43.2) operation***, exam***, 
subject***, operation 
× exam***
LAGB (b) 60.5 (55.8; 65.6) 54.3 (49.9; 58.9) 53.2 (48.9; 57.8)
P (c) 59.6 (55.1; 64.4) 67.2 (62.1; 72.7) 60.5 (55.8; 65.5)
a-b, a-c Exam 1 (a) Exam 2 (b) Exam 3 (c) a–b, a–c
Potentiation factor 
ratio
BPD (a) 1.28 (1.16; 1.42) 1.10 (0.99; 1.19) 1.13 (1.03; 1.24) operation*
LAGB (b) 1.30 (1.19; 1.43) 1.29 (1.19; 1.42) 1.24 (1.15; 1.36)
P (c) 1.32 (1.21; 1.44) 1.36 (1.25; 1.48) 1.25 ( 1.15; 1.37)
a-b, a-c Exam 1 (a) Exam 2 (b) Exam 3 (c) a–b, a–c
Rate sensitivity, 
pmol/m2/mmol/l
BPD (a) 1,348 (943; 1,856) 932 (576; 1,406) 1,228 (827; 1,740)  
LAGB (b) 1,203 (873; 1,606) 1,284 (937; 1,706) 1,084 (799; 1,428)
P (c) 1,337 (1006; 1,733) 891 (651; 1,184) 1,110 (801; 1,487)
 Exam 1 (a) Exam 2 (b) Exam 3 (c)  
Table 2 continued on next page
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 Effects on T2DM Improvement  
 At the 6-month time point, in the BPD group T2DM was resolved in 9/16 subjects (60%), 
whilst in 6/16 (40%) it was significantly improved. Accordingly, in the LAGB group, T2DM 
was resolved in 3/16 (19%) of the subjects and improved in 10/16 (63%). Finally, in the P 
group, T2DM was resolved in 4/20 (20%) patients and improved in 12/20 (60%). The mean 
HbA1c decreased significantly in all study groups, whilst the drop between the study time 
points was most prominent in the BPD group ( table 2 ).
 Effects on Insulin Sensitivity and Beta Cell Function  
 Table 2 presents the key outcomes with respect to insulin sensitivity and beta cell function 
for our study cohort. Insulin sensitivity improved after all three types of operations. Indeed, 
HOMA-IR decreased similarly after all three operations, whilst glucose disposal (Mk per FFM) 
increased significantly and similarly in all study groups, especially after 1 month. 
 The total secretory demand on beta cells was reduced markedly only after the BPD, while 
the basal insulin secretion decreased significantly after all three operations, with the most 
marked decrease in the BPD group. However, the total insulin secretion decreased signifi-
cantly only in the BPD group in Exam 2 versus 1 and in Exam 3 versus 1, whereas it did not 
change significantly following the operation in the LAGB and P group ( table 2 ). 
 In addition, the potentiation factor ratio tended to decrease after BPD, whereas it did not 
change significantly after the operation in the LAGB or the P group. 
 Moreover, neither the beta cell glucose sensitivity nor the rate sensitivity exhibited 
significant changes after any of the three study operations. 
 Finally, the hepatic insulin extraction increased significantly in the BPD group in Exam 2 
versus 1 and in Exam 3 versus 1, whereas it did not change significantly following the oper-
ation in the LAGB or the P group. 
 Effects on MMT Glucose/Insulin Parameters and Selected Gastrointestinal Hormones 
 Blood glucose levels during the MMT decreased between Exam 1 and 2 in all three study 
groups ( fig. 1 i). Moreover, insulin levels also decreased after all three types of operations in 
this study; this effect was more pronounced in the BPD group ( fig. 1 ii). The insulin curve 
following the BPD in Exam 2 and 3 was more flat than in Exam 1 ( fig. 1 ii).
 For C-peptide, the changes in Exam 2 and 3 differed according to operation (Operation × 
Exam: F = 40.5, p < 0.001) ( fig. 1 iii). C-peptide levels decreased between Exam 1 and 2, and 
Table 2. Continued
Parameter Operation Exam 1 Exam 2 Exam 3 ANOVA††
Glucose sensitivity, 
pmol/m2/mmol/l
BPD (a) 68.9 (51.8; 89.7) 54.8 (40.4; 72.5) 64.4 (48.2; 84.2)  
LAGB (b) 61.0 (47.2; 77.5) 92.2 (73.4; 114.3) 88.6 (70.4; 110.2)
P (c) 58.6 (45.6; 73.9) 74.5 (59.1; 92.6) 82.3 (65.2; 102.4)
 Exam 1 (a) Exam 2 (b) Exam 3 (c)  
Hepatic insulin 
extraction, %
BPD 59.6 (55.8; 63.2) 78.2 (75.4; 80.9) 77.3 (74.3; 80.2) operation***, exam***, 
subject**, operation × 
exam***
LAGB 60.6 (57.4; 63.7) 63.9 (60.8; 66.8) 64.1 (61.0; 66.9)
P 61.3 (58.2; 64.4) 64.5 (61.5; 67.4) 64.2 (61.1; 67.2)
a-b, a-c Exam 1 (a) Exam 2 (b) Exam 3 (c) a–b, a–c
 +Significant difference for multiple comparisons (p<0.05); significant difference for ANOVA factors and between-factor 
interaction *p<0.05, **p<0.01, ***p<0.001. 
††Adjusted for age and BMI.
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between Exam 1 and 3 in the LAGB and BPD group and between Exam 2 and 3 in the P group. 
Furthermore, in the BPD group, the C-peptide curve in Exam 2 and Exam 3 was more flat than 
in Exam 1 ( fig. 1 iii).
 GIP levels decreased in Exam 2 and remained lower in Exam 3 in the BPD group ( fig.  2 i). 
Conversely, GIP levels increased in the P group, whereas they did not change significantly in 
the LAGB group ( fig. 2 i).
 GLP-1 levels increased from Exam 1 to Exam 2 and then remained unchanged in the BPD 
group ( fig. 2 ii). Moreover, in the LAGB group GLP-1 levels did not change significantly from 
Exam 1 to Exam 2, but increased between Exam 2 and 3; whereas in the P group they did not 
change significantly from Exam 1 to Exam 2 and decreased between Exam 2 and 3 ( fig. 2 ii). 
 Finally, glucagon levels did not change significantly after the operation in any of the three 
study groups ( fig. 2 iii). 
 Discussion 
 To our knowledge, this is the first study in obese T2DM patients reporting the effects of 
the emerging bariatric technique P on insulin resistance and secretion in comparison to 
established bariatric procedures such as the LAGB and BPD. Our study results indicate that 
insulin sensitivity improves similarly after all these bariatric operations. However, only the 
BPD resulted in significantly decreased total insulin secretion during the 6-month follow-up 
period, and it was also more effective compared with the LAGB and the P in improving T2DM 
within this timeframe.
 Our study results are in accord with recent meta-analysis data on predictors of T2DM 
remission after bariatric surgery in obese subjects  [18] . Indeed, T2DM resolution was noted 
in 89% of the patients after BPD, while lower rates were noted following Roux en Y gastric 
bypass (RYGB), LAGB, and sleeve gastrectomy (SG). Of note, in this meta-analysis the only 
significant predictor of HbA1c reduction was waist circumference. Interestingly, T2DM 
remission was independent of the initial BMI of the patients when the groups with BMI < 35 
kg/m 2 and BMI  ≥ 35 kg/m 2 were compared  [18] . 
 It should be noted that the primary objective of the present study was to compare the 
effects of P (a bariatric operation that can be categorized between purely restrictive and 
malabsorptive bariatric procedures) with an established restrictive procedure (i.e., LAGB) 
and a predominantly malabsorptive procedure (i.e., BPD). Verdi et al.  [19] have recently 
reported a study comparing the effects of P to those of laparoscopic SG, a bariatric operation 
that can be also categorized between the purely restrictive and the malabsorptive bariatric 
procedures. This study documented greater weight loss following SG; however, the study 
cohort included obese subjects without diabetes, and additional metabolic effects were not 
followed up  [19] .
 Moreover, in another recent study Robert et al.  [20] reported that short diabetes duration 
( ≤ 4 years), good preoperative glycemic control, BMI  ≤ 50 kg/m 2 , and absence of insulin 
therapy constitute predictive factors of T2DM remission at 1 year after bariatric surgery. 
Additionally, in this study there was no significant difference for T2DM remission at 1 year 
with regard to the surgical procedure, i.e., LAGB, RYGB, or SG  [20] . Contrary, the data from 
our cohorts indicate a higher T2DM remission rate in patients treated with BPD, followed by 
those receiving LAGB and P  [21] . Importantly, a UK population-based cohort study with more 
than 500 diabetic patients treated by bariatric surgery documented the highest T2DM 
remission rate after RYGB, followed by SG, and LAGB  [22] – results which are similar to the 
findings of our study. Interestingly, the potent BPD effect on hyperglycemia has also been 
shown in patients with moderate obesity or overweight  [10] . Indeed, Scopinaro et al.  [10] 
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have reported that BPD improves or resolves T2DM in subjects with BMI ranging from 25 to 
35 kg/m 2 without causing excessive weight loss, potentially due to improved insulin sensi-
tivity and beta cell function. Of note, in this study there was a markedly different response 
between morbidly obese patients and patients with lower BMI, potentially due to a different 
beta cell defect, whilst T2DM resolution correlated positively with BMI  [10] . 
 Limitations of our study were as follows: The number of patients is the rather low number 
of patients although the examinations of patients were very detailed. Only selected methods 
of bariatric surgery, i.e., the procedures usually performed in our bariatric center, were eval-
uated, and some usually applied methods such as sleeve gastrectomy and RYGB were not 
included . 
 Overall, compiling data indicate that bariatric surgery results in better glycemic control 
in obese T2DM patients compared to medical treatment  [23, 24] . Importantly, different post-
operative effects/outcomes following different types of bariatric procedures appear to be 
related to distinct mechanisms contributing to improved insulin sensitivity and/or secretion 
 [1, 4, 25] . As such, the LAGB effect is considered mostly weight loss-dependent  [1, 4, 25] , 
whilst P may exert effects that are not only related to food restriction and weight loss but are 
also mediated through distinct incretin/hormonal effects  [5, 6] . Potential mechanisms that 
have been suggested for incretin/hormonal changes following P include i) devascularization 
of the greater curvature and therefore decreased blood supply to some of the active cells in 
the stomach (lowering their secretion); ii) effects on the mechanical constriction of the 
plicated/infolded stomach tissue; iii) interference in the majority of the vagal nerve fibers 
alongside the greater curvature of the stomach; and iv) potentially quicker gastric evacuation 
time. These mechanisms are relatively similar to those considered to mediate the effects of 
SG  [1, 5, 6] . On the other hand, proposed mechanisms for the metabolic outcomes of BPD 
include i) malabsorption and ii) limited contact of pancreatic enzymes with ingested food in 
 Fig. 1. Blood glucose, insulin and C-peptide levels during the MMT in the BPD, LAGB and P study groups at 
the three study time points (before the operation (Exam 1) and at 1 month (Exam 2) and 6 months (Exam 3) 
after the operation).  i) Blood glucose levels during the MMT. Symbols: BPD – triangles; LAGB – squares; P – 
circles, Exam 1 – white symbols; Exam 2 – light grey symbols; Exam 3 –dark grey symbols.  A, B, C – all three 
study groups : operation: F = 71.3, p < 0.001; exam: F = 323.7, p < 0.001; time: F = 61.5, p < 0.001; operation × 
exam: F = 10.5, p < 0.001; operation × time: F = 2, p = 0.005; exam × time: F = 0.8, p = 0.73; operation × exam 
× time: F = 0.9, p = 0.591; subject: F = 28.4, p < 0.001.  D – BPD study group : exam: F = 182.9, p < 0.001; time: 
F = 8.7, p < 0.001; exam × time: F = 0.9, p = 0.617; subject: F = 26.6, p < 0.001.  E – LAGB study group : exam:
F = 105.6, p < 0.001; time: F = 32.4, p < 0.001; exam × time: F = 0.3, p = 1; subject: F = 51.6, p < 0.001.  F – P 
study group : exam: F = 51.3, p < 0.001; time: F = 25.3, p < 0.001; exam × time: F = 1, p = 0.502; subject: F = 
50.3, p < 0.001.  ii) Insulin levels during the MMT. Symbols: BPD – triangles; LAGB – squares; P – circles, Exam 
1 – white symbols; Exam 2 – light grey symbols; Exam 3 – dark grey symbols.  A, B, C – all three study groups : 
operation: F = 86.5, p < 0.001; exam: F = 194.5, p < 0.001; time: F = 216.3, p < 0.001; operation × exam: F = 
35.1, p < 0.001; operation × time: F = 7.8, p < 0.001; exam × time: F = 1.1, p = 0.327; operation × exam × time: 
F = 2.1, p < 0.001; subject: F = 33.3, p < 0.001.  D – BPD study group : exam: F = 354.7, p < 0.001; time: F = 43.1, 
p < 0.001; exam × time: F = 3.2, p < 0.001; subject: F = 98.6, p < 0.001.  E – LAGB study group : exam: F = 43.3, 
p < 0.001; time: F = 101.4, p < 0.001; exam × time: F = 1.1, p = 0.363; subject: F = 14.8, p < 0.001.  F – P study 
group : exam: F = 8.1, p < 0.001; time: F = 102.2, p < 0.001; exam × time: F = 1.9, p = 0.011; subject: F = 30.3, 
p < 0.001.  iii) C-peptide levels during the MMT. Symbols: BPD – triangles; LAGB – squares; P – circles, Exam 
1 – white symbols; Exam 2 – light grey symbols; Exam 3 – dark grey symbols.  A, B, C – all three study groups : 
operation: F = 78.7, p < 0.001; exam: F = 136.1, p < 0.001; time: F = 231.1, p < 0.001; operation × exam: F = 
40.5, p < 0.001; operation × time: F = 6.7, p < 0.001; exam × time: F = 1, p = 0.51; operation × exam × time:
F = 2, p < 0.001; subject: F = 36.8, p < 0.001.  D – BPD study group : exam: F = 168.5, p < 0.001; time: F = 35.6, 
p < 0.001; exam × time: F = 2.6, p < 0.001; subject: F = 60.6, p < 0.001.  E – LAGB study group : exam: F = 56,
p < 0.001; time: F = 112.8, p < 0.001; exam × time: F = 0.9, p = 0.631; subject: F = 37.9, p < 0.001.  F – P study 
group : exam: F = 11.5, p < 0.001; time: F = 114.5, p < 0.001; exam × time: F = 1.7, p = 0.037; subject: F = 26.8, 
p < 0.001. 
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the distal ileum but also iii) contact of undigested food with the ileal mucosa leading to a 
potentiated incretin effect and iv) acceleration and intensification of the enterohepatic circu-
lation of bile acids  [4, 25] . 
 In our study, insulin sensitivity, measured by HOMA-IR, as well as by euglycemic clamp 
tests, improved in a similar way after all three study operations. Other studies have reported 
greater improvement of HOMA-IR and QUICKI following BPD compared with LAGB  [26] . Simi-
larly, Tsoli et al.  [27] have shown greater improvement in insulin sensitivity after BPD 
compared to SG. Such different results may be attributed to the heterogeneous patient cohorts 
studied, while it should be also noted that HOMA-IR is a surrogate marker primarily of hepatic 
insulin resistance, whereas glucose disposal during the euglycemic clamp measures insulin 
sensitivity mainly in skeletal muscles. 
 Furthermore, in agreement with results from previously published studies  [28] , total 
insulin secretion in our study decreased significantly only in the BPD group. However, it 
cannot be excluded that the decreased insulin levels after BPD may be also attributed to the 
increased hepatic insulin clearance. Notably, we did not observe an increase in beta cell 
glucose sensitivity in the 6-month period after any of the three study operations. Interest-
ingly, insufficient increase of beta cell glucose sensitivity has also been reported in non-obese 
diabetic patients 1 year after BPD, even in subjects with T2DM remission  [29] . Moreover, Mari 
et al.  [14] have also reported nonsignificant changes in beta cell glucose sensitivity in 11 
morbidly obese T2DM patients after BPD. Nevertheless, BPD appears to result in T2DM reso-
lution in a greater proportion of subjects when compared with LAGB and P. A possible expla-
nation for these observations could be that the beta cell glucose sensitivity is basically 
secretion normalized to glucose levels; thus, insulin secretion is decreased after the BPD, and 
glucose levels decrease as well, but in proportion to the decrease in insulin secretion. Accord-
 Fig. 2. GIP, GLP-1 and glucagon levels during the MMT in the BPD, LAGB and P study groups at the three study 
time points (before the operation (Exam 1) and at 1-month (Exam 2) and 6-months (Exam 3) after the op-
eration).  i) GIP levels during the MMT. Symbols: BPD – triangles; LAGB – squares; P – circles, Exam 1 – white 
symbols; Exam 2 – light grey symbols; Exam 3 – dark grey symbols.  A, B, C – all three study groups : operation: 
F = 135.4, p < 0.001; exam: F = 3.9, p = 0.022; time: F = 178.5, p < 0.001; operation × exam: F = 10.3, p < 0.001; 
operation × time: F = 0.4, p = 0.944; exam × time: F = 2, p = 0.007; operation × exam × time: F = 11.5, p < 0.001; 
subject: F = 23.5, p < 0.001.  D – BPD study group : exam: F = 53.3, p < 0.001; time: F = 29.1, p < 0.001; exam × 
time: F = 3.6, p < 0.001; subject: F = 12.5, p < 0.001.  E – LAGB study group : exam: F = 0.6, p = 0.547; time: F = 
77.6, p < 0.001; exam × time: F = 0.9, p = 0.551; subject: F = 8.6, p < 0.001.  F – P study group : exam: F = 10.4, 
p < 0.001; time: F = 108.7, p < 0.001; exam × time: F = 1.5, p = 0.135; subject: F = 20.1, p < 0.001.  ii) GLP-1 
levels during the MMT. Symbols: BPD – triangles; LAGB – squares; P – circles, Exam 1 – white symbols; Exam 
2 – light grey symbols; Exam 3 – dark grey symbols.  A, B, C – all three study groups : operation: F = 0.9, p = 0.39; 
exam: F = 1.8, p = 0.161; time: F = 14.4, p < 0.001; operation × exam: F = 2.7, p = 0.003; operation × time: F = 
0.7, p = 0.734; exam × time: F = 0.5, p = 0.957; operation × exam × time: F = 12.7, p < 0.001; subject: F = 9.2, 
p < 0.001.  D – BPD study group : exam: F = 19.4, p < 0.001; time: F = 1.6, p = 0.167; exam × time: F = 0.6, p = 
0.823; subject: F = 9.5, p < 0.001.  E – LAGB study group : exam: F = 8.2, p < 0.001; time: F = 6.7, p < 0.001; exam 
× time: F = 0.9, p = 0.576; subject: F = 15.2, p < 0.001.  F – P study group : exam: F = 3.6, p = 0.031; time: F = 
15.3, p < 0.001; exam × time: F = 0.8, p = 0.619; subject: F = 24.1, p < 0.001.  iii) Glucagon levels during the 
MMT. Symbols: BPD – triangles; LAGB – squares; P – circles, Exam 1 – white symbols; Exam 2 – light grey 
symbols; Exam 3– dark grey symbols.  A, B, C – all three study groups : operation: F = 11.8, p < 0.001; exam:
F = 7.3, p < 0.001; time: F = 12.9, p < 0.001; operation × exam: F = 2.2, p = 0.015; operation × time: F = 0.6,
p = 0.858; exam × time: F = 0.3, p = 0.998; operation × exam × time: F = 12, p < 0.001; Subject: F = 1, p = 0.435. 
 D – BPD study group : exam: F = 1.2, p = 0.316; time: F = 1.4, p = 0.245; exam × time: F = 0.8, p = 0.605; subject: 
F = 18.7, p < 0.001.  E – LAGB study group : exam: F = 3.6, p = 0.031; time: F = 4.5, p < 0.001; exam × time: F = 
0.6, p = 0.828; subject: F = 14.3, p < 0.001.  F – P study group : exam: F = 2, p = 0.138; time: F = 9, p < 0.001; 
exam × time: F = 0.2, p = 0.993; subject: F = 6.1, p < 0.001. 
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ingly, beta cell glucose sensitivity, reflecting the ratio between insulin secretion and glucose 
levels, does not change significantly. However, more research is required to elucidate the 
regulation of glucose sensitivity in T2DM patients following complex bariatric procedures, 
such as the BPD. 
 Notably, beta cell dysfunction may also persist after RYGB, even in patients with T2DM 
remission  [30] . This impairment can be rescued by oral glucose stimulation, suggesting that 
RYGB leads to an important gastrointestinal effect  [30] . Similar results have been shown after 
gastric banding, indicating that beta cell function does not fully recover even in cases of 
clinical T2DM resolution  [31] . Finally, in our study we documented a decrease in the secretion 
of GIP and an increase in the secretion of GLP-1 after BPD, being consistent with results from 
previous studies. Indeed, Tsoli et al.  [27] reported significantly increased GLP-1 and peptide 
YY responses during oral glucose tolerance test after both BPD and SG. 
 In conclusion, we have found similar improvement in insulin sensitivity in obese T2DM 
women after all three types of bariatric operations during a 6-month postoperative follow-up 
period. Of note, only BPD led to a significant decrease in the demand of beta cells (decreased 
integrated insulin secretion during the MMT), but without increasing significantly the beta 
cell glucose sensitivity. Long-term follow-up is scheduled for this study cohort in order to 
prospectively explore the long-term outcomes of LAGB, P, and BPD at a 1-, 2-, and 4-year post-
operative follow-up.
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